Literature DB >> 20145545

IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion.

Sabine Huenecke1, Stefanie Yvonne Zimmermann, Stephan Kloess, Ruth Esser, Andrea Brinkmann, Lars Tramsen, Melanie Koenig, Stephanie Erben, Christian Seidl, Torsten Tonn, Angelika Eggert, Alexander Schramm, Peter Bader, Thomas Klingebiel, Thomas Lehrnbecher, Jakob Robert Passweg, Jan Soerensen, Dirk Schwabe, Ulrike Koehl.   

Abstract

To characterize natural killer (NK) cell subpopulations during activation, we analyzed the NK cell receptor repertoire and functionality of purified clinical scale CD56CD3 donor NK cells during stimulation with 1000 U/mL interleukin (IL)-2 for up to 14 days. In a phase I/II trial, we investigated the efficacy and feasibility of nonidentical NK cell infusion in patients with neuroblastoma after haploidentical stem cell transplantation. After IL-2 stimulation, large differences in the distribution of CD16 and CD16 subpopulations were found in 12 donors. Thereby, surface expression for all natural cytotoxicity receptors (NCRs) and NKG2D increased. In addition, killer cell immunoglobulin-like receptor (KIR) NK cells were overgrown by KIR proportion and the homing receptor CD62L was lost during stimulation. NK cell cytotoxicity against K562 and neuroblastoma cells increased and significantly higher cytokine secretion (eg, interferon-gamma, tumor necrosis factor-beta, macrophage inflammatory protein-1alpha, macrophage inflammatory protein-1beta) was observed after IL-2 stimulation compared with freshly isolated NK cells. However, NK cells of donors showing an initially enhanced cytotoxicity combined with NCR and CD69 expression, seemed to be exhausted and did not favor a stimulation period over 9 days. When IL-2-stimulated NK cells were given to transplant recipients, they induced a decrease of peripheral blood NK, in particular of CD56-NK cells. Our data indicate that IL-2 stimulation increases the expression of activating receptors and emphasizes mechanisms beside KIR/human leukocyte antigen. Furthermore, the results suggest that the expansion period of purified NK cells has to be individualized to optimize NK cell immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20145545     DOI: 10.1097/CJI.0b013e3181bb46f7

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  40 in total

1.  Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model.

Authors:  Melissa A Geller; David A Knorr; David A Hermanson; Lee Pribyl; Laura Bendzick; Valarie McCullar; Jeffrey S Miller; Dan S Kaufman
Journal:  Cytotherapy       Date:  2013-10       Impact factor: 5.414

2.  Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the γc cytokines and TGF-β1.

Authors:  Yuk Pheel Park; Seung-Chul Choi; Patricia Kiesler; Aleksandra Gil-Krzewska; Francisco Borrego; Jennifer Weck; Konrad Krzewski; John E Coligan
Journal:  Blood       Date:  2011-08-03       Impact factor: 22.113

Review 3.  Engineering Natural Killer Cells for Cancer Immunotherapy.

Authors:  Katayoun Rezvani; Rayne Rouce; Enli Liu; Elizabeth Shpall
Journal:  Mol Ther       Date:  2017-06-28       Impact factor: 11.454

4.  Human natural killer cells exhibit direct activity against Aspergillus fumigatus hyphae, but not against resting conidia.

Authors:  Stanislaw Schmidt; Lars Tramsen; Mitra Hanisch; Jean-Paul Latgé; Sabine Huenecke; Ulrike Koehl; Thomas Lehrnbecher
Journal:  J Infect Dis       Date:  2010-12-14       Impact factor: 5.226

5.  Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade.

Authors:  Ines Pires da Silva; Anne Gallois; Sonia Jimenez-Baranda; Shaukat Khan; Ana C Anderson; Vijay K Kuchroo; Iman Osman; Nina Bhardwaj
Journal:  Cancer Immunol Res       Date:  2014-02-11       Impact factor: 11.151

Review 6.  Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy.

Authors:  Dominique Bollino; Tonya J Webb
Journal:  Transl Res       Date:  2017-06-09       Impact factor: 7.012

7.  Membrane-type 6 matrix metalloproteinase regulates the activation-induced downmodulation of CD16 in human primary NK cells.

Authors:  Giovanna Peruzzi; Laurette Femnou; Aleksandra Gil-Krzewska; Francisco Borrego; Jennifer Weck; Konrad Krzewski; John E Coligan
Journal:  J Immunol       Date:  2013-07-12       Impact factor: 5.422

8.  Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.

Authors:  E Liu; Y Tong; G Dotti; H Shaim; B Savoldo; M Mukherjee; J Orange; X Wan; X Lu; A Reynolds; M Gagea; P Banerjee; R Cai; M H Bdaiwi; R Basar; M Muftuoglu; L Li; D Marin; W Wierda; M Keating; R Champlin; E Shpall; K Rezvani
Journal:  Leukemia       Date:  2017-07-20       Impact factor: 11.528

Review 9.  Natural killer cells and antifungal host response.

Authors:  Stanislaw Schmidt; Stefanie-Yvonne Zimmermann; Lars Tramsen; Ulrike Koehl; Thomas Lehrnbecher
Journal:  Clin Vaccine Immunol       Date:  2013-01-30

10.  Increased sMICA and TGFβ1 levels in HNSCC patients impair NKG2D-dependent functionality of activated NK cells.

Authors:  Stephan Klöß; Nicole Chambron; Tanja Gardlowski; Lubomir Arseniev; Joachim Koch; Ruth Esser; Wolfgang Glienke; Oliver Seitz; Ulrike Köhl
Journal:  Oncoimmunology       Date:  2015-05-29       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.